Moreover, a recent study shows that depletion/inhibition of Mps1 fails to kill p53-deficient/mutated cells more efficiently than cells expressing wild-type p53 [233], suggesting that Mps1 or BubR1 inhibition may offer a better therapeutic benefit for cancer patients expressing wild-type p53. This evidence concerns the gene TP53 and cancer.